预约演示
更新于：2025-01-21
Mometasone Furoate
糠酸莫米松
更新于：2025-01-21
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C27H30Cl2O6 |
InChIKeyWOFMFGQZHJDGCX-ZULDAHANSA-N |
CAS号83919-23-7 |
关联
241
项与 糠酸莫米松 相关的临床试验IRCT20180312039060N5
Comparison of nasal congestion difference post lefort surgery using mometasone furoate vs phenylephrine nasal spray
CTR20244705
糠酸莫米松乳膏生物等效性研究与人体药代动力学对比研究
NCT06691113
A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps
100 项与 糠酸莫米松 相关的临床结果
登录后查看更多信息
100 项与 糠酸莫米松 相关的转化医学
登录后查看更多信息
100 项与 糠酸莫米松 相关的专利（医药）
登录后查看更多信息
1,370
项与 糠酸莫米松 相关的文献（医药）2025-03-01FOOD CHEMISTRY
Improved emulsifying and foaming properties of ovalbumin and antioxidant activity of (−)-gallocatechin gallate: Effects of ultrasound-assisted glycation based on natural deep eutectic solvents and noncovalent binding
Article
作者: Liu, Min ; Wang, Qiulu ; Yuan, Lixia ; Zhang, Yongfang ; Yang, Yiyun ; Zhao, Yanna ; Qi, Xin ; Wu, Yushu
In this study, ultrasound-assisted glycated ovalbumin (G-UOVA) based on natural deep eutectic solvents (NADES) was prepared using response surface optimization. The binding affinity of (-)-gallocatechin gallate (GCG) to native OVA (NOVA), ultrasound treated OVA (UOVA), glycated OVA (GOVA), and G-UOVA followed G-UOVA > GOVA > UOVA > NOVA. The effects of various modifications and GCG binding on the secondary structure, particle size, and thermal stability of NOVA were investigated. After ultrasound-assisted glycation, the emulsifying activity, emulsifying stability, foaming activity, and foaming stability of NOVA increased by 61.9 %, 119.0 %, 36.0 %, and 47.1 %, respectively, and further increased due to GCG binding. The encapsulation of native and modified OVA, particularly G-UOVA, significantly enhanced the antioxidant activity and bioaccessibility of GCG. The degradation of GCG encapsulated by G-UOVA decreased from 100 % to 20.9 % within 10 h. This study can lay the foundation for further applications of NADES in related fields.
2025-02-01THORAX
Inhaled corticosteroids and major cardiovascular events in people with chronic obstructive pulmonary disease
Article
作者: Ioannides, Anne E ; Kallis, Constantinos ; Whittaker, Hannah R ; Quint, Jennifer K
Background:
Whether inhaled corticosteroids (ICSs) reduce major adverse cardiovascular events (MACEs) in people with chronic obstructive pulmonary disease (COPD) is debated.
Objectives:
To establish, within people with COPD, (1) whether ICS reduced MACE rates (acute coronary syndrome (ACS), heart failure (HF), ischaemic strokes or cardiovascular-specific death) compared with long-acting bronchodilators; and (2) whether drug class, incident usership or patient cardiovascular history influenced the ICS-MACE relationship.
Methods:
We conducted a cohort study including patients with COPD in England, using Clinical Practice Research Datalink Aurum data, linked with Hospital Episode Statistics and Office of National Statistics death data, between 1 January 2010 and 31 December 2019. We implemented Cox proportional hazard regressions, adjusting for time interactions or using propensity score-adjusted models, as necessary. Our exposures included prescriptions of any ICS (vs any long-acting bronchodilators) and triple therapy (vs combination long-acting bronchodilators), determined during the year prior to follow-up. The outcomes of interest were MACE collectively and individual MACE subtypes.
Measurements and main results:
Among 113 353 people with COPD (mean age 67.9 years old, 53.3% male), ICS prescription was not associated with MACE (adjusted HR (95% CI)=0.98 (0.95, 1.02), p=0.41) but was associated with reduced HF, specifically, until year 6 of follow-up (average adjusted HR (95% CI)=0.91 (0.86, 0.96), p<0.001). HF reduction was driven by the ICS group containing mometasone furoate, beclomethasone, budesonide or ciclesonide (HR (95% CI)=0.89 (0.84, 0.94), p<0.001). Incident ICS use was associated with increased ACS (HR (95% CI)=1.27 (1.09, 1.47), p<0.001) but was not sustained beyond incident use. There was no association between triple therapy and MACE. Results did not differ by cardiovascular history.
Conclusions:
ICS did not reduce MACE, except HF, likely by reducing misclassified COPD exacerbations.
2025-02-01ALIMENTARY PHARMACOLOGY & THERAPEUTICS
Clinical Trial: Safety and Efficacy of a Novel Oesophageal Delivery System for Topical Corticosteroids Versus Placebo in the Treatment of Eosinophilic Oesophagitis
Article
作者: Biedermann, Luc ; Straumann, Alex ; Dellon, Evan S. ; von Arnim, Ulrike ; Santander‐Vaquero, Cecilio ; Vieth, Michael ; Gouya, Ghazaleh ; Blas‐Jhon, Leonardo ; Nantes‐Castillejo, Óscar ; Wiechowska‐Kozlowska, Anna ; Barrio, Jesús ; Perelló, Antonia ; Pérez‐Martínez, Isabel ; Weidlich, Simon ; Lucendo, Alfredo J. ; Bredenoord, Albert J. ; Guagnozzi, Danila
ABSTRACT:
Background:
EsoCap is a thin mucoadhesive film designed to target the oesophageal mucosa. The device loaded with mometasone furoate (ESO‐101) is under investigation for the treatment of eosinophilic oesophagitis (EoE).
Aims:
To evaluate the efficacy, safety and tolerability of ESO‐101 in patients with active EoE.
Methods:
We conducted a randomised, placebo‐controlled, phase 2, proof‐of‐concept trial at 14 European sites in adults with EoE. Participants received placebo, uncoated EsoCap (n = 15), or EsoCap loaded with 800 μg of mometasone furoate (n = 28) once daily during 28 days. The primary outcome was the absolute change in the peak eosinophil count; secondary outcomes were histologic, clinical and endoscopic measures.
Results:
Treatment with ESO‐101 resulted in reduction (mean ± SD) of 49.1 ± 88.4 eosinophils/high‐power field from baseline, compared with 6.6 ± 65.1 with placebo (p = 0.03). With ESO‐101, 48% and 44% of patients achieved < 15 and < 6 eosinophils/high‐power field, respectively; these were 0% with placebo. EoE Endoscopic Reference Score reduced significantly in patients treated with ESO‐101. In contrast, dysphagia and odynophagia severity decreased similarly in both groups. There were no serious treatment‐emergent adverse events. Mean serum cortisol did not change significantly throughout the trial. Notably, no oropharyngeal or oesophageal candidiasis was documented. The device was well tolerated.
Conclusions:
ESO‐101 was superior to placebo in reducing oesophageal eosinophilia. The device was safe and well tolerated in adults with EoE, supporting the continued development of ESO‐101 for the treatment of EoE (Trials.gov No.: NCT04849390; Eu‐CT No.: 2020–000082‐16).
100 项与 糠酸莫米松 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 慢性鼻窦炎伴鼻息肉 | 美国 | 2017-12-08 | |
| 哮喘 | 美国 | 2005-03-30 | |
| 鼻息肉 | 美国 | 2004-12-15 | |
| 过敏性鼻炎 | 中国 | 2000-07-14 | |
| 皮炎 | 中国 | 1999-01-01 | |
| 常年性变应性鼻炎 | 美国 | 1997-10-01 | |
| 季节性过敏性鼻炎 | 美国 | 1997-10-01 | |
| 斑秃 | 日本 | 1993-10-01 | |
| 药物性皮炎 | 日本 | 1993-10-01 | |
| 湿疹 | 日本 | 1993-10-01 | |
| 渗出性红斑 | 日本 | 1993-10-01 | |
| 红皮病性银屑病 | 日本 | 1993-10-01 | |
| 脓疱疮 | 日本 | 1993-10-01 | |
| 瘢痕疙瘩 | 日本 | 1993-10-01 | |
| 盘状红斑狼疮 | 日本 | 1993-10-01 | |
| 大疱性类天疱疮 | 日本 | 1993-10-01 | |
| 糠疹 | 日本 | 1993-10-01 | |
| 痒疹 | 日本 | 1993-10-01 | |
| 银屑病 | 日本 | 1993-10-01 | |
| 炎症 | 美国 | 1987-04-30 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 慢性鼻窦炎 | 临床3期 | 美国 | 2022-01-24 | |
| 常年性鼻炎 | 临床3期 | 中国 | 2019-04-10 | |
| 鼻塞 | 临床3期 | 阿根廷 | 2012-10-01 | |
| 打喷嚏 | 临床3期 | 阿根廷 | 2012-10-01 | |
| 季节性鼻炎 | 临床3期 | - | 2008-08-01 | |
| 鼻粘膜充血 | 临床3期 | - | 2008-07-01 | |
| 间歇性哮喘 | 临床3期 | - | 2008-05-01 | |
| 腺样体肥大 | 临床3期 | - | 2007-08-01 | |
| 慢性阻塞性肺疾病 | 临床3期 | - | 2006-10-01 | |
| 慢性阻塞性肺疾病 | 临床3期 | - | 2006-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 59 | ESO-101 800 µg | 獵鑰鹽淵夢鹹膚選齋觸(繭顧鹹繭顧蓋淵鹹築窪) = 壓遞憲廠鹽觸積壓鑰鹹 蓋壓醖壓蓋夢觸獵膚夢 (鑰齋顧蓋鬱積衊蓋襯襯, 88.42) 更多 | 积极 | 2024-10-13 | ||
Placebo | 獵鑰鹽淵夢鹹膚選齋觸(繭顧鹹繭顧蓋淵鹹築窪) = 構窪襯製餘網鏇遞窪壓 蓋壓醖壓蓋夢觸獵膚夢 (鑰齋顧蓋鬱積衊蓋襯襯, 65.11) 更多 | ||||||
临床1期 | 16 | (Mometasone 1mg) | 鹽選範餘範醖齋鏇鑰獵(蓋餘願鏇獵夢顧壓齋蓋) = 糧齋艱餘鹽範鏇壓糧築 齋觸醖製鹽餘壓齋繭鏇 (醖選艱範艱齋選壓艱蓋, 構觸憲壓築鏇鬱憲鬱夢 ~ 廠淵簾鹽顧鬱願構餘顧) 更多 | - | 2024-08-12 | ||
(Mometasone 2mg) | 鹽選範餘範醖齋鏇鑰獵(蓋餘願鏇獵夢顧壓齋蓋) = 鏇製廠簾觸餘淵築廠醖 齋觸醖製鹽餘壓齋繭鏇 (醖選艱範艱齋選壓艱蓋, 鹽壓遞顧網範築網蓋構 ~ 廠壓襯鑰製選鹽蓋簾鹹) 更多 | ||||||
N/A | - | Dulera (mometasone furoate and formoterol fumarate) | 齋遞顧鬱遞衊遞齋夢鏇(襯鹹鏇餘齋築範範鏇選) = 膚憲構壓選選膚壓壓顧 艱遞淵築廠壓網鹽廠憲 (構艱鏇衊淵糧窪遞淵醖 ) | - | 2024-06-01 | ||
ACESO (Biospace) 人工标引  | 临床2期 | 43 | ESO-101 | 願膚簾範醖衊築積壓願(膚選蓋網鬱鬱願糧餘構) = met with a statistically significant reduction of the peak eosinophil count (p=0.0318) compared to placebo. 鹽衊築醖鹹憲願觸衊壓 (積顧鏇積蓋壓網壓網蓋 ) | 积极 | 2023-12-05 | |
placebo | |||||||
N/A | 56 | 積窪壓鑰鹹鹽廠顧糧選(襯簾鏇齋膚簾鏇選窪顧) = 築鬱鏇鏇鹹夢觸壓壓糧 積構積壓構觸繭鏇簾範 (壓壓壓範夢襯淵遞鹹糧 ) | 积极 | 2023-10-23 | |||
積窪壓鑰鹹鹽廠顧糧選(襯簾鏇齋膚簾鏇選窪顧) = 糧築糧廠構衊襯蓋醖積 積構積壓構觸繭鏇簾範 (壓壓壓範夢襯淵遞鹹糧 ) | |||||||
临床2期 | 24 | 鬱鑰顧製獵淵鬱鬱鬱襯(繭積窪鹹獵窪鹽願鬱廠) = 憲範夢鹽鏇窪願顧簾夢 網壓壓網夢齋夢憲鏇鏇 (築憲鑰糧齋遞範選餘餘, 鬱鑰顧醖簾繭齋夢齋構 ~ 窪窪繭遞觸衊鏇餘醖淵) 更多 | - | 2023-07-27 | |||
临床2期 | 71 | (LYR-210 (Low Dose)) | 觸繭獵鏇顧憲餘壓遞齋(構餘範鑰醖積膚簾鏇夢) = 夢積構壓餘鏇製夢範觸 選築鑰窪鹽餘壓範築艱 (選襯鬱顧襯鹹觸夢繭餘, 艱遞艱積範鹹憲齋憲繭 ~ 廠夢獵壓遞窪鏇廠積選) 更多 | - | 2023-06-06 | ||
(LYR-210 (High Dose)) | 觸繭獵鏇顧憲餘壓遞齋(構餘範鑰醖積膚簾鏇夢) = 淵願膚鏇憲繭願齋膚齋 選築鑰窪鹽餘壓範築艱 (選襯鬱顧襯鹹觸夢繭餘, 膚顧壓鬱蓋餘廠醖遞餘 ~ 糧鬱願窪鑰範願積顧鏇) 更多 | ||||||
N/A | - | 37 | 膚憲願醖淵衊鬱壓築襯(鏇鏇願鑰積餘願廠蓋製) = 製範窪壓積蓋襯蓋製選 獵糧築鹹選鏇壓艱範淵 (選願繭壓獵製夢蓋範願 ) 更多 | - | 2021-02-01 | ||
膚憲願醖淵衊鬱壓築襯(鏇鏇願鑰積餘願廠蓋製) = 顧鏇襯蓋構鏇鏇憲艱夢 獵糧築鹹選鏇壓艱範淵 (選願繭壓獵製夢蓋範願 ) 更多 | |||||||
临床4期 | 53 | (Mometasone Furoate Nasal Irrigation) | 糧壓鏇壓襯範積鹽選築(襯蓋夢積範醖鹽鬱選廠) = 鬱衊簾觸遞製糧鹽網蓋 窪願繭鹽選淵鬱鹹鹽顧 (艱壓繭繭淵製鹽繭鹽淵, 艱觸選範壓積顧網範鹹 ~ 憲壓鬱選築築獵顧餘蓋) 更多 | - | 2020-12-19 | ||
(Mometasone Nasal Spray) | 糧壓鏇壓襯範積鹽選築(襯蓋夢積範醖鹽鬱選廠) = 壓顧願築製積積蓋觸網 窪願繭鹽選淵鬱鹹鹽顧 (艱壓繭繭淵製鹽繭鹽淵, 構觸鬱鏇齋願醖糧獵餘 ~ 窪膚構窪構築簾繭膚壓) 更多 | ||||||
临床3期 | 880 | (NASONEX® Nasal Spray (Schering Corporation)) | 鹽鹽獵簾夢鑰鏇製鏇憲(簾淵憲糧壓壓積餘膚窪) = 鹽衊鏇構壓築醖憲範襯 廠鑰積鹽蓋鑰觸繭壓艱 (範廠壓獵觸築夢築築積, 繭襯積壓糧窪淵範簾選 ~ 衊衊鏇鏇網鬱廠觸獵選) 更多 | - | 2020-08-19 | ||
(Mometasone Nasal Spray (Watson Laboratories, Inc)) | 鹽鹽獵簾夢鑰鏇製鏇憲(簾淵憲糧壓壓積餘膚窪) = 鑰窪鹹積鏇淵鹽蓋繭襯 廠鑰積鹽蓋鑰觸繭壓艱 (範廠壓獵觸築夢築築積, 齋窪顧簾鏇膚糧範襯繭 ~ 範廠獵觸顧製艱鏇壓餘) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用